Cogent Biosciences, Inc. COGT
Regular-session close
After hours · Nov 20, 5:14 PM ET
- YTD
- -24.79%
- 1 year
- -23.01%
5D -0.36 (-1.25%)
- Market cap
- 4.65B
- EPS (ttm)
- -2.26
- Shares out
- 173.99M
- Forward P/E
- -21.07
- YTD return
- -24.79%
- 1-year return
- -23.01%
- 50-day average
- 30.84
- 200-day average
- 35.12
- Enterprise value
- 4.35B
- Price / book
- 10.30
- Volume
- 2.12M
- Avg volume
- 2.07M
- Open
- 27.26
- Previous close
- 27.74
- Day's range
- 26.62 – 27.83
- 52-week range
- 26.36 – 43.73
- Beta
- 0.34
- Analysts
- Strong Buy
- Price target
- 55.82 (+108.9%)
- Earnings date
- Feb 16, 2027
Key statistics
- Free cash flow
- -191.62M
- Total cash
- 791.13M
- Total debt
- 244.22M
- Return on equity
- -99.59%
- Short % of float
- 10.07%
Fundamental scorecard
3 of 25 checks passed on COGT’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 45.00
- Target (mean)
- 55.82
- Target (high)
- 61.00
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -0.63612.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -0.63 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.56362 | -0.59 | -0.03 | -4.68% |
| Aug 10, 2026 | Jun 30, 2026 | -0.55497 | -0.52 | +0.03 | +6.30% |
| May 5, 2026 | Mar 31, 2026 | -0.53 | -0.53 | 0.00 | 0.00% |
| Feb 17, 2026 | Dec 31, 2025 | -0.51 | -0.55 | -0.04 | -7.84% |
| Nov 7, 2025 | Sep 30, 2025 | -0.54 | -0.50 | +0.04 | +7.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| May 29, 2026 | Wedbush | reit | Outperform | Outperform |
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cogentbio.com
News
Your note
Sign in to keep a note on COGT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | Sale | Jan 21, 2026 | 0 |
| GREEN JOHN L | Chief Financial Officer | Sale | Dec 25, 2025 | 131,834 |
| KEARNS EVAN D J.D. | Officer | Sale | Dec 25, 2025 | 109,398 |
| MORRIS ARLENE M. | Director | Conversion of Exercise of derivative security | Aug 26, 2026 | 0 |
| PINNOW COLE | Officer | Stock Award(Grant) | Dec 16, 2025 | 216,650 |
| ROBBINS ANDREW R. | Chief Executive Officer | Stock Gift | May 18, 2026 | 657,503 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.43% | 26,852,012 | 717.35M | Sep 29, 2026 |
| Blackrock Inc. | 9.90% | 17,228,842 | 460.27M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.67% | 8,131,026 | 217.22M | Sep 29, 2026 |
| State Street Corporation | 4.47% | 7,770,149 | 207.58M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.28% | 7,448,057 | 198.97M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 4.27% | 7,432,956 | 198.57M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.96% | 5,156,952 | 137.77M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 4,316,858 | 115.32M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.24% | 3,900,938 | 104.21M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.14% | 3,724,033 | 99.49M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.44% | 2,509,157 | 67.03M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.36% | 2,358,212 | 63.00M | Jun 29, 2026 |
